MP0533, a CD3-Engaging Darpin Targeting CD33, CD123, and CD70 in Patients with Relapsed/Refractory AML or MDS/AML: Preliminary Results of a Phase 1/2a Study

CD33 医学 抗原 细胞因子释放综合征 内科学 耐受性 肿瘤科 免疫学 免疫疗法 癌症研究 干细胞 不利影响 川地34 生物 癌症 嵌合抗原受体 遗传学
作者
Thomas Pabst,Mojca Jongen‐Lavrencic,Steffen Boettcher,Geert A. Huls,David C. de Leeuw,Philippe Legenne,Mariola Dymkowska,Christiane Andrieu,Oliver Schönborn‐Kellenberger,Paul Baverel,Zita Arany,Elena Fernández,Anne Goubier,Vladimir Kirkin,Nicolas Leupin,Marion Subklewe
出处
期刊:Blood [Elsevier BV]
卷期号:142 (Supplement 1): 2921-2921 被引量:5
标识
DOI:10.1182/blood-2023-173353
摘要

BACKGROUND: The development of targeted immunotherapy for acute myeloid leukemia (AML) is challenging due to the clonal heterogeneity of the disease and the lack of single AML-specific target antigens. MP0533 is a multi-specific, half-life extended CD3-engaging DARPin (Designed Ankyrin Repeat Protein). It simultaneously targets CD33, CD123, and CD70, thereby enabling avidity-driven T cell-mediated killing of leukemic stem cells (LSCs) and malignant blast cells known to co-express these targets. MP0533's affinity to each target is tuned to preferentially kill malignant cells which co-express at least two of these three antigens, while preserving a therapeutic window towards healthy cells. MP0533 was shown to induce a tumor-specific endogenous T-cell response in ex vivo samples from AML patients and led to T-cell-mediated eradication of tumors in AML xenograft mouse models, with limited cytokine release or other serious adverse reactions (Bianchi et al., Blood 2022;140[Suppl 1]:2251-2). Herein, we present early observations of the first three MP0533 dose-escalation regimens (DR) of the ongoing first-in-human, multicenter, single-arm, open-label, phase 1/2a study. METHODS: The objectives of this ongoing trial are to evaluate the safety/tolerability, pharmacokinetics (PK), and pharmacodynamics, as well as preliminary antileukemic activity of MP0533 monotherapy in patients with relapsed/refractory (R/R) AML or myelodysplastic syndrome (MDS)/AML (NCT05673057). Patients with an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2, and a life expectancy of ≥12 weeks are eligible. Up to 45 patients will be enrolled in the dose-escalation part of the trial. Patients receive MP0533 once per week starting at day 15 after a stepwise dose increase on days 1, 5, and 8, and until disease progression or unacceptable toxicity. One cycle corresponds to 28 days. DR escalation of MP0533 is guided by two Bayesian logistic regression models estimating the joint probability of cytokine release syndrome (CRS) and non-CRS dose-limiting toxicities (DLTs). Bone marrow examinations are performed at weeks 4, 8, and 12. Responses are determined using 2022 European LeukemiaNet (ELN) criteria with an assessment of hematologic improvement. Treatment-emergent adverse events (TEAEs) are assessed according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0. RESULTS: As of data cut-off (20 July 2023), 5 patients received ≥5 infusions of MP0533 across 3 DRs preceded by step-up dosing (1 patient each at DR 1 and DR 2, respectively, and 3 patients at DR 3), including 2 women and 3 men. The median age at enrollment was 79 years (range 68-81). All patients had adverse risk mutations. Patients received a median number of 1 prior antileukemic therapy line (range 1-2) and on average 2 cycles of MP0533 treatment (range 1-3). To date, one patient with a TP53 mutation achieved a morphologic leukemia-free state after 8 weeks and complete remission with incomplete hematologic recovery (CRi) after 12 weeks of treatment with DR 3. No DLTs have been observed in any DR so far. TEAEs considered to be related to MP0533 were Grade 2 infusion-related reaction (2 patients), Grade 1 CRS (2 patients), and Grade 1 diarrhea and fatigue (1 patient). No Grade ≥3 drug-related TEAEs were reported. The reported TEAEs (Figure) reflected the patients' disease course. Preliminary PK results up to DR 3 confirmed that all patients were exposed to MP0533 and exposure levels were broadly aligned with PK/PD model predictions of MP0533 in serum. CONCLUSION: The results of this ongoing phase 1/2a study indicated an acceptable safety profile of MP0533 monotherapy in 5 patients up to DR 3 with weekly infusions. Preliminary response data are encouraging, with one response observed in 1 of 2 patients evaluable for response in DR 3 to date.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
云朝完成签到,获得积分10
刚刚
1秒前
1秒前
ZeKaWa的应助被liu采纳,获得10
1秒前
PEACE完成签到 ,获得积分20
1秒前
儒雅黑猫完成签到 ,获得积分10
1秒前
2秒前
思恩Shen发布了新的文献求助10
2秒前
秦风完成签到,获得积分10
3秒前
杜欣悦发布了新的文献求助10
3秒前
香蕉觅云的应助被顺利毕业mpa采纳,获得10
3秒前
94完成签到,获得积分10
3秒前
fighting完成签到,获得积分10
4秒前
5秒前
5秒前
哈47发布了新的文献求助10
6秒前
俭朴含卉完成签到 ,获得积分10
6秒前
饼饼完成签到,获得积分20
6秒前
虚幻明杰完成签到,获得积分10
6秒前
Johnny发布了新的文献求助10
7秒前
wxz1998完成签到,获得积分10
7秒前
O基米德发布了新的文献求助10
7秒前
8秒前
田様的应助被木头采纳,获得10
8秒前
吱哦周完成签到,获得积分10
11秒前
12秒前
Diamond完成签到,获得积分10
12秒前
饼饼发布了新的文献求助10
12秒前
13秒前
秋风的应助被紧张的紫文采纳,获得10
14秒前
14秒前
思恩Shen完成签到,获得积分20
15秒前
16秒前
路小雨发布了新的文献求助10
17秒前
xiao完成签到,获得积分10
20秒前
兔兔完成签到,获得积分10
20秒前
21秒前
聪明的秋天完成签到,获得积分10
22秒前
moexce完成签到,获得积分10
22秒前
离研通完成签到,获得积分10
23秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181839
求助须知:如何正确求助?哪些是违规求助? 9571584
关于积分的说明 21818707
捐赠科研通 7778124
什么是DOI,文献DOI怎么找? 3433524
关于科研通互助平台的介绍 2557710
邀请新用户注册赠送积分活动 2479621